Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Huilong Li x
  • Refine by Access: All content x
Clear All Modify Search
Restricted access

Xiaopan Yang, Xiaojing Fan, Jiangyue Feng, Tinghui Fan, Jingfei Li, Linfei Huang, Luming Wan, Huan Yang, Huilong Li, Jing Gong, Yanhong Zhang, Qi Gao, Fei Zheng, Lei Xu, Haotian Lin, Dandan Zhang, Hongbin Song, Yufei Wang, Xueping Ma, Zhiwei Sun, Cheng Cao, Xiaoli Yang, Hui Zhong, Yi Fang, and Congwen Wei

Golgi protein 73 (GP73), also called Golgi membrane protein 1 (GOLM1), is a resident Golgi type II transmembrane protein and is considered as a serum marker for the detection of a variety of cancers. A recent work revealed the role of the secreted GP73 in stimulating liver glucose production and systemic glucose homeostasis. Since exaggerated hepatic glucose production plays a key role in the pathogenesis of type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM), GP73 may thus represent a potential therapeutic target for treating diabetic patients with pathologically elevated levels. Here, in this study, we found that the circulating GP73 levels were significantly elevated in T2DM and positively correlated with hemoglobin A1c. Notably, the aberrantly upregulated GP73 levels were indispensable for the enhanced protein kinase A signaling pathway associated with diabetes. In diet-induced obese mouse model, GP73 siRNA primarily targeting liver tissue was potently effective in alleviating abnormal glucose metabolism. Ablation of GP73 from whole animals also exerted a profound glucose-lowering effect. Importantly, neutralizing circulating GP73 improved glucose metabolism in streptozotocin (STZ) and high-fat diet/STZ-induced diabetic mice. We thus concluded that GP73 was a feasible therapeutic target for the treatment of diabetes.